Progressive Multifocal Leukoencephalopathy Clinical Trial
— PENALTYOfficial title:
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
This study aims to assess the efficacy and safety of pembrolizumab in immunocompromised patients with progressive multifocal leukoencephalopathy (PML). This phase II, multicenter, single-arm study includes patients with an underlying cause of immunosuppression hardly reversible, i.e. not the patients with HIV nor those receiving biologics for chronic inflammatory diseases. Patients will receive intravenous pembrolizumab (2 mg/kg, maximum 200 mg) at month 0, 1 and 2 (total of three doses). The primary endpoint will be achieving at least one negative result of JCV viral load in cerebrospinal fluid (CSF) within the M0 to M3 period.
Status | Not yet recruiting |
Enrollment | 33 |
Est. completion date | April 2028 |
Est. primary completion date | April 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 years old 2. Diagnosis of definite PML since less than 2 months according to American Academy of Neurology 3. Presence of JCV in the CSF in the last CSF sampling. 4. Signed informed consent (from the patient, or if unable to consent, from a surrogate) 5. For women of childbearing potential: negative serum or urine b-HCG test and agree to use a highly effective contraception methods during 8 months (i.e. until 6 months after end of experimental treatment) Exclusion Criteria: 1. Patients in whom immune reconstitution is achievable (HIV infection - Multiple sclerosis - Auto-immune and inflammatory diseases) 2. Patients who have received solid organ transplantation 3. Hypersensitivity to the active substance or to any of the excipients 4. Life expectancy less than 1 month 5. Pregnancy or lactating women or planning birth during the study period 6. Having previously been treated by anti-PD1mAb 7. Patient receiving IL-2 or IL-7 for the treatment of PML at inclusion 8. Patient whose weight is > 100kg 9. Participation in other interventional study [a patient already included in another interventional study for which the treatment can lead to an immunodepression can be included if: - the investigational treatment has been completed and there is no risk of drug interaction with the administration of Pembrolizumab as defined in PENALTY study - if this does not alter the study's ability to evaluate the effect of Pembrolizumab in terms of safety and efficacy (from the investigator's point of view)] 10. Patient without national health insurance, and patient on AME (state medical aid) 11. Patient under guardianship or curatorship 12. Patient deprived of their liberty by a judicial or administrative decision |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Pitié-Salpêtrière - Médecine Intensive Réanimation | Paris | |
France | Hôpital Pitié-Salpêtrière - Service d'hématologie clinique | Paris | |
France | Hôpital Pitié-Salpêtrière - Service des Maladies infectieuses et tropicales | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Negativation of JCV viral load in the CSF as assessed by PCR: at least one JCV PCR in the CSF negative in the Day 0 to Month 3 period | At baseline (Day 0), 1 month, 2 months and 3 months | ||
Secondary | Negativation of JCV PCR viral load in the CSF: cumulative incidence of negative JCV viral load measures by PCR in CSF, with death as competing event | At baseline (Day 0), 1 month, 2 months and 3 months | ||
Secondary | Evolution of the JCV viral load in the CSF (repeated measures JCV PCR in CSF) | At baseline (Day 0), 1 month, 2 months and 3 months | ||
Secondary | Repositivation of JCV PCR: at least a positive result following at least a negative result | At baseline (Day 0), 1 month, 2 months and 3 months | ||
Secondary | Evolution of National Institutes of Health Stroke Scale (NIHSS) score | Repeated measures of neurological status | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | |
Secondary | Evolution of 6-item Modified Rankin Scale score (includes death as most severe state) | Repeated measures of degree of disability or dependence in the daily activities in neurological conditions | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | |
Secondary | Evolution of Glasgow Outcome Scale Extended (GOS-E) score | Repeated measures of neurological outcome and degree of disability in neurological conditions | At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months | |
Secondary | Relapse or progression | Adjudication by a dedicated committee ; based on clinical evolution, JCV PCR in CSF, brain MRI | From baseline to end of participation, a maximum of 12 months | |
Secondary | Death (and date of death) | From baseline to end of participation, a maximum of 12 months | ||
Secondary | Cause specific death: death related to PML | Adjudication by a dedicated committee | From baseline to end of participation, a maximum of 12 months | |
Secondary | Any adverse event classified by using US NCI CTCAE | From baseline to end of participation, a maximum of 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01211639 -
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
|
N/A | |
Completed |
NCT02004444 -
JC Virus Reactivation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05849467 -
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
|
Phase 1 | |
Recruiting |
NCT01730131 -
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
|
||
Recruiting |
NCT04781309 -
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
|
Early Phase 1 | |
Completed |
NCT02694783 -
Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells
|
Early Phase 1 | |
Completed |
NCT01132053 -
Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
|
||
Completed |
NCT03399981 -
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
|
||
Terminated |
NCT00746941 -
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
|
Phase 1/Phase 2 | |
Completed |
NCT02895581 -
Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy
|
N/A | |
Recruiting |
NCT04453917 -
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
|
N/A | |
Not yet recruiting |
NCT05541549 -
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML
|
Phase 2 | |
Recruiting |
NCT04091932 -
Treatment of PD-1 Inhibitor in AIDS-associated PML
|
Phase 2 |